265 related articles for article (PubMed ID: 32057323)
61. Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis.
Chen H; Tao R; Zhao H; Jiang J; Yang J
Medicine (Baltimore); 2020 Jan; 99(5):e19000. PubMed ID: 32000440
[TBL] [Abstract][Full Text] [Related]
62. New anticoagulants in cancer patient treatments.
Arobelidze S; Haddad A; Spiro T; Daw H
Anticancer Drugs; 2016 Oct; 27(9):832-8. PubMed ID: 27387143
[TBL] [Abstract][Full Text] [Related]
63. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
[TBL] [Abstract][Full Text] [Related]
64. [Cancer and venous thromboembolism recurrence: The keys for an optimal management].
Mahé I; Benhamou Y; Helfer H; Chidiac J
Bull Cancer; 2018 May; 105(5):508-516. PubMed ID: 29544692
[TBL] [Abstract][Full Text] [Related]
65. Edoxaban in venous thromboembolism and stroke prevention: an appraisal.
Proietti M; Lip GY
Vasc Health Risk Manag; 2016; 12():45-51. PubMed ID: 27013883
[TBL] [Abstract][Full Text] [Related]
66. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
67. Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer.
van der Hulle T; den Exter PL; van den Hoven P; van der Hoeven JJ; van der Meer FJ; Eikenboom J; Huisman MV; Klok FA
Chest; 2016 May; 149(5):1245-51. PubMed ID: 26836911
[TBL] [Abstract][Full Text] [Related]
68. Inpatient thromboprophylaxis use in U.S. hospitals: adherence to the seventh American College of Chest Physician's recommendations for at-risk medical and surgical patients.
Amin AN; Stemkowski S; Lin J; Yang G
J Hosp Med; 2009 Oct; 4(8):E15-21. PubMed ID: 19827045
[TBL] [Abstract][Full Text] [Related]
69. Prediction and Prevention of Cancer-Associated Thromboembolism.
Khorana AA; DeSancho MT; Liebman H; Rosovsky R; Connors JM; Zwicker J
Oncologist; 2021 Jan; 26(1):e2-e7. PubMed ID: 33274815
[TBL] [Abstract][Full Text] [Related]
70. Safety of anticoagulant treatment in cancer patients.
Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
[TBL] [Abstract][Full Text] [Related]
71. [Management of Venous Thromboembolism in Cancer Patients].
Madoiwa S
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2064-2071. PubMed ID: 29361618
[TBL] [Abstract][Full Text] [Related]
72. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
73. Clinical outcomes and adherence to guideline recommendations during the initial treatment of acute venous thromboembolism.
Martinez K; Kosirog E; Billups SJ; Clark NP; Delate T; Witt DM
Ann Pharmacother; 2015 Aug; 49(8):869-75. PubMed ID: 25931575
[TBL] [Abstract][Full Text] [Related]
74. Use of direct oral anti-coagulants for the treatment of venous thromboembolism in patients with advanced cancer: a prospective observational study.
Oyakawa T; Muraoka N; Iida K; Kusuhara M; Mori K
Int J Clin Oncol; 2019 Jul; 24(7):876-881. PubMed ID: 30756270
[TBL] [Abstract][Full Text] [Related]
75. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.
Lyman GH
Cancer; 2011 Apr; 117(7):1334-49. PubMed ID: 21425133
[TBL] [Abstract][Full Text] [Related]
76. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
Farge D; Frere C; Connors JM; Khorana AA; Kakkar A; Ay C; Muñoz A; Brenner B; Prata PH; Brilhante D; Antic D; Casais P; Guillermo Esposito MC; Ikezoe T; Abutalib SA; Meillon-García LA; Bounameaux H; Pabinger I; Douketis J;
Lancet Oncol; 2022 Jul; 23(7):e334-e347. PubMed ID: 35772465
[TBL] [Abstract][Full Text] [Related]
77. Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis.
Mahé I; Chidiac J; Helfer H; Noble S
J Thromb Haemost; 2016 Nov; 14(11):2107-2113. PubMed ID: 27566698
[TBL] [Abstract][Full Text] [Related]
78. Rethinking the approach to thrombosis in patients with cancer.
Khorana AA
Vasc Med; 2020 Jun; 25(3):208-209. PubMed ID: 31718489
[No Abstract] [Full Text] [Related]
79. Quality Improvement at an Academic Cancer Center: Venous Thromboembolism Prophylaxis in Patients With Multiple Myeloma.
Baz R; Furman R; Simondsen K; Stone C
Cancer Control; 2020; 27(2):1073274820930204. PubMed ID: 32551873
[TBL] [Abstract][Full Text] [Related]
80. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.
Khorana AA; Streiff MB; Farge D; Mandala M; Debourdeau P; Cajfinger F; Marty M; Falanga A; Lyman GH
J Clin Oncol; 2009 Oct; 27(29):4919-26. PubMed ID: 19720907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
